Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 20/20 | 1.00 |
| ▸ | MMP13 | P45452 | 20/20 | 1.00 |
| ▸ | MMP2 | P08253 | 2/20 | 0.80 |
| ▸ | MMP3 | P08254 | 2/20 | 0.80 |
| ▸ | MMP9 | P14780 | 2/20 | 0.80 |
| ▸ | MMP8 | P22894 | 2/20 | 0.80 |
| ▸ | MMP12 | P39900 | 1/20 | 0.53 |
| ▸ | MMP14 | P50281 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6994418 | 1.00 | MMP1 (1.00) | MMP1MMP13MMP2MMP3MMP9 | |
| SCHEMBL7001256 | 0.90 | MMP1 (0.82) | MMP1MMP13MMP2MMP3MMP9 | |
| SCHEMBL7001259 | 0.90 | MMP1 (0.82) | MMP1MMP13MMP2MMP3MMP9 | |
| SCHEMBL6994719 | 0.89 | MMP1 (1.00) | MMP1MMP13MMP2MMP3MMP9 | |
| SCHEMBL6996574 | 0.89 | MMP1 (1.00) | MMP1MMP13MMP2MMP3MMP9 | |
| SCHEMBL6994722 | 0.89 | MMP1 (1.00) | MMP1MMP13MMP2MMP3MMP9 | |
| SCHEMBL7000080 | 0.88 | MMP1 (0.79) | MMP1MMP13MMP2MMP3MMP9 | |
| SCHEMBL7000077 | 0.88 | MMP1 (0.79) | MMP1MMP13MMP2MMP3MMP9 | |
| SCHEMBL250645 | 0.86 | MMP1 (0.76) | MMP1MMP13MMP2MMP3MMP9 | |
| SCHEMBL7000970 | 0.85 | MMP1 (0.74) | MMP1MMP13MMP2MMP3MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240083855-A1 | JAK2 AND ALK2 INHIBITORS AND METHODS FOR THEIR USE | SUMITOMO PHARMA AMERICA, INC. (US) | 2024-03-14 | — | — | US | disclosed |
| EP-1070069-B1 | BICYCLIC HYDROXAMIC ACID DERIVATIVES | PFIZER PROD INC (US) | 2003-07-16 | — | — | EP | disclosed |
| US-6110964-A | FOR TREATING ARTHRITIS, INFLAMMATORY BOWEL DISEASE, CROHN'S DISEASE, EMPHYSEMA, ACUTE RESPIRATORY DISTRESS SYNDROME, ASTHMA CHRONIC OBSTRUCTIVE PULMONARY DISEASE, ALZHEIMER'S DISEASE, ORGAN TRANSPLANT TOXICITY, CACHEXIA, CANCER | PFIZER INC. (US) | 2000-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240083855-A1 | JAK2 AND ALK2 INHIBITORS AND METHODS FOR THEIR USE | ALK, JAK2, JAK1 | MMP1 2298/4885MMP13 2440/4885MMP2 2512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.